age
Item
age 30-65 y
boolean
C0001779 (UMLS CUI [1])
diabetes mellitus type 2
Item
healthy lean, obese, or known type 2 diabetic
boolean
C0011849 (UMLS CUI [1,1])
C0441730 (UMLS CUI [1,2])
body mass index
Item
body mass index (bmi) less than 36
boolean
C1305855 (UMLS CUI [1])
Oral Glucose Tolerance Test
Item
all nondiabetic subjects must have normal oral glucose tolerance
boolean
C0029161 (UMLS CUI [1])
laboratory parameters
Item
subjects must have the following laboratory values:
boolean
C0022885 (UMLS CUI [1])
hematocrit
Item
1. hematocrit ≥ 35 vol%
boolean
C0518014 (UMLS CUI [1])
serum creatinine
Item
2. serum creatinine ≤ 1.6 mg/dl
boolean
C0201976 (UMLS CUI [1])
aspartate aminotransferase
Item
3. aspartate aminotransferase (ast) (sgot)< 2 times upper limit of normal
boolean
C0201899 (UMLS CUI [1])
alanine aminotransferase
Item
4. alanine aminotransferase (alt) (sgpt)< 2 times upper limit of normal
boolean
C0201836 (UMLS CUI [1])
alkaline phosphatase
Item
5. alkaline phosphatase < 2 times upper limit of normal
boolean
C0201850 (UMLS CUI [1])
triglycerides
Item
6. triglycerides < 150 mg/dl
boolean
C0202236 (UMLS CUI [1])
prothrombin time
Item
7. prothrombin time (pt) 11.7 -14.3 seconds
boolean
C0491338 (UMLS CUI [1])
partial thromboplastin time
Item
8. partial thromboplastin time 23.0-37.0 seconds
boolean
C3525810 (UMLS CUI [1])
glucose metabolism; diabetes mellitus type 2
Item
no diseases known to affect glucose metabolism other than healthy type 2 diabetes
boolean
C0596620 (UMLS CUI [1])
C0011849 (UMLS CUI [2,1])
C0441730 (UMLS CUI [2,2])
Thiazide Diuretics; beta-blockers; estrogens therapy; systemic glucocorticoids
Item
subjects must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable dose of such agents for the past three months before entry into the study. subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months. subjects taking systemic glucocorticoids are excluded.
boolean
C0012802 (UMLS CUI [1])
C0001645 (UMLS CUI [2])
C3541386 (UMLS CUI [3])
C3540777 (UMLS CUI [4])
heart disease; nyha classification; peripheral vascular disease; pulmonary disease
Item
subjects with a history of clinically significant heart disease (new york heart classification greater than grade ii; more than non-specific st-t wave changes on the ekg), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied.
boolean
C0018799 (UMLS CUI [1])
C1275491 (UMLS CUI [2])
C0085096 (UMLS CUI [3])
C0024115 (UMLS CUI [4])
Pulmonary Embolism; retinopathy; retinal hemorrhage; uncontrolled hypertension; blood pressure; neuropathy
Item
recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, systolic bp>180, diastolic bp>105, autonomic neuropathy, resting heart rate >100, electrolyte abnormalities.
boolean
C0034065 (UMLS CUI [1])
C0035309 (UMLS CUI [2])
C0035317 (UMLS CUI [3])
C1868885 (UMLS CUI [4])
C0005823 (UMLS CUI [5])
C0442874 (UMLS CUI [6])